Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AOC3 | Q16853 | 1/20 | 0.54 |
| ▸ | NPC1 | O15118 | 3/20 | 0.50 |
| ▸ | RAB9A | P51151 | 3/20 | 0.50 |
| ▸ | CA12 | O43570 | 1/20 | 0.50 |
| ▸ | CA9 | Q16790 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | CA2 | P00918 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | CES2 | O00748 | 1/20 | 0.46 |
| ▸ | CES1 | P23141 | 1/20 | 0.46 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | GLA | P06280 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrazine SCHEMBL8651254 | 0.98 | AOC3 (0.52) | AOC3NPC1RAB9ACA12CA9 | |
| Hydrochloric Acid SCHEMBL10536523 | 0.98 | AOC3 (0.52) | AOC3NPC1RAB9ACA12CA9 | |
| SCHEMBL28119878 | 0.90 | HDAC3 (0.55) | AOC3RAB9AALDH1A1KMT2AMEN1 | |
| SCHEMBL29851956 | 0.88 | AOC3 (0.52) | AOC3NPC1RAB9ACA12CA9 | |
| SCHEMBL11693547 | 0.88 | NPC1 (0.53) | AOC3NPC1RAB9ACA12CA9 | |
| SCHEMBL1920895 | 0.86 | AOC3 (0.50) | AOC3NPC1RAB9ACA12CA9 | |
| SCHEMBL3188486 | 0.86 | AOC3 (0.50) | AOC3NPC1RAB9ACA12CA9 | |
| Hydrochloric Acid SCHEMBL27460406 | 0.85 | AOC3 (0.48) | AOC3NPC1RAB9ACA12CA9 | |
| SCHEMBL10416109 | 0.85 | AOC3 (0.54) | AOC3NPC1RAB9ACA12CA9 | |
| SCHEMBL10782311 | 0.83 | NPC1 (0.48) | AOC3NPC1RAB9ACA12CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 616 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4719485-A1 | ANTIBODY-DRUG CONJUGATES FOR TREATING INFECTIONS OF HUMAN IMMUNODEFICIENCY VIRUS (HIV) | Taimed Biologics Inc. (TW) | 2026-04-08 | — | — | EP | claimed |
| EP-4642491-A1 | METHOD FOR GLYCOPROTEIN MODIFICATION | Honeybear Biosciences Inc. (TW) | 2025-11-05 | — | — | EP | claimed |
| WO-2025072355-A1 | METHODS FOR AND COMPOSITIONS OF NON-PEG BIOCONJUGATES WITH ULTRA-HIGH DRUG-TO-AGENT RATIO | BIOHYBRID SOLUTIONS HOLDINGS, INC. (US) | 2025-04-03 | — | — | WO | claimed |
| US-20240398969-A1 | ANTIBODY-DRUG CONJUGATES FOR TREATING INFECTIONS OF HUMAN IMMUNODEFICIENCY VIRUS (HIV) | TAIMED BIOLOGICS INC. (TW) | 2024-12-05 | — | — | US | claimed |
| WO-2024245401-A1 | ANTIBODY-DRUG CONJUGATES FOR TREATING INFECTIONS OF HUMAN IMMUNODEFICIENCY VIRUS (HIV) | TAIMED BIOLOGICS INC. (CN) | 2024-12-05 | — | — | WO | claimed |
| US-20240238432-A1 | METHOD FOR GLYCOPROTEIN MODIFICATION | HONEYBEAR BIOSCIENCES INC. (TW) | 2024-07-18 | — | — | US | claimed |
| WO-2024098002-A1 | CALCIUM VOLTAGE-GATED CHANNEL AUXILIARY SUBUNIT GAMMA 1 (CACNG1) BINDING PROTEINS AND CACNG1-MEDIATED DELIVERY TO SKELETAL MUSCLE | REGENERON PHARMACEUTICALS, INC. (US) | 2024-05-10 | — | — | WO | claimed |
| WO-2024026345-A2 | EXTRACELLULAR VESICLE-ASO CONSTRUCTS TARGETING CEBP/BETA | LONZA SALES AG (CH) | 2024-02-01 | — | — | WO | claimed |
| WO-2024006813-A2 | METHODS OF USING EXTRACELLULAR VESICLE-ASO TARGETING STAT6 | LONZA SALES AG (CH) | 2024-01-04 | — | — | WO | claimed |
| EP-4294456-A1 | EXTRACELLULAR VESICLE LINKED TO A BIOLOGICALLY ACTIVE MOLECULE VIA AN OPTIMIZED LINKER AND AN ANCHORING MOIETY | Lonza Sales AG (CH) | 2023-12-27 | — | — | EP | claimed |
| WO-2005105830-A1 | INTERLEUKIN-1 RECEPTOR ANTAGONISTS, COMPOSITIONS, AND METHODS OF TREATMENT | VALORISATION-RECHERCHE, SOCIETE EN COMMANDITE (CA) | 2005-11-10 | — | — | WO | claimed |
| EP-1472279-A1 | A METHOD FOR INHIBITING \"MELANOMA INHIBITORY ACTIVITY\" MIA | Antisense Pharma GmbH (DE) | 2004-11-03 | — | — | EP | claimed |
| EP-0987249-B1 | Process for the preparation of benzyl carbazates | BAYER CHEMICALS AG (DE) | 2004-03-17 | — | — | EP | claimed |
| WO-2003064457-A1 | A METHOD FOR INHIBITING 'MELANOMA INHIBITORY ACTIVITY' MIA | ANTISENSE PHARMA GMBH (DE) | 2003-08-07 | — | — | WO | claimed |
| EP-0672678-B1 | Azapeptide derivative | FUJIREBIO KK (JP) | 2000-10-25 | — | — | EP | claimed |
| EP-0987249-A1 | Process for the preparation of benzyl carbazates | Bayer Aktiengesellschaft (DE) | 2000-03-22 | — | — | EP | claimed |
| EP-0518655-B1 | Solid phase peptide synthesis | ZENECA LTD (GB) | 1997-09-10 | — | — | EP | claimed |
| EP-0672678-A1 | Azapeptide derivative | FUJIREBIO Inc. (JP) | 1995-09-20 | — | — | EP | claimed |
| EP-0518655-A2 | Solid phase peptide synthesis | ZENECA LIMITED (GB) | 1992-12-16 | — | — | EP | claimed |
| EP-0000815-B1 | PROCESS FOR PREPARING N-ARYL OR N-ARALKYL SUBSTITUTED URETHANES | MITSUI TOATSU CHEMICALS, Inc. (JP) | 1982-01-27 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240398969-A1 | ANTIBODY-DRUG CONJUGATES FOR TREATING INFECTIONS OF HUMAN IMMUNODEFICIENCY VIRUS (HIV) | CD4, FCGR3B, FCGR1A | AOC3 3761/4885NPC1 925/4885RAB9A 762/4885 |
| US-20240238432-A1 | METHOD FOR GLYCOPROTEIN MODIFICATION | SIGLEC7, FUT5, FUT6 | AOC3 1997/4885NPC1 900/4885RAB9A 1327/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.